Refine
Language
- English (2)
Has Fulltext
- yes (2)
Is part of the Bibliography
- no (2)
Keywords
- additive manufacturing (1)
- liver cancer (1)
- open-source 3D bioprinting (1)
- organoids (1)
- stereolithography (1)
- tumor microenvironment (1)
- tumor model (1)
This research introduces a new 3D bioprinter that incorporates live imaging of the bioprinted tissue with high resolution and high-speed capabilities. The printer employs a light sheet-based system to photocrosslink polymers into hydrogels at a printing speed of up to 0.66 mm³/s with a resolution of 15.7 µm. A significant advancement of this bioprinter is its ability to track cells and bioink during crosslinking, which enables real- time evaluation of the 3D-bioprinted structure’s quality. Fibroblast cells were encapsulated using this method, and the viability was evaluated directly after bioprinting and seven days after encapsulation, which was found to be high (83% ± 4.34%). Furthermore, a full- thickness skin construct was bioprinted and maintained in culture for 6 weeks, demonstrating the long-term viability and physiological relevance of the bioprinted tissue. The usage of solid-state laser beam scanning devices could enhance bioprinting’s speed and precision. This fast and accurate light-based bioprinter offers a promising platform for generating customizable 3D-printed structures with viable long-term cultures.
A widespread application of 3D bioprinting in basic and translational research requires accessibility to affordable printers able to produce physiologically relevant tissue models. To facilitate the use of bioprinting as a standard technique in biology, an open-source device based on a consumer-grade 3D stereolithography apparatus (SLA) printer is developed. This SLA bioprinter can produce complex constructs that preserve cell viability and recapitulate the physiology of tissues. The detailed documentation of the modifications apported to the printer as well as a throughout performance analysis allow for a straightforward adoption of the device in other labs and its customization for specific applications. Given the low cost, several modified bioprinters could be simultaneously operated for a parallelized tissue production. To showcase the capability of the bioprinter, constructs consisting of patient-derived cholangiocarcinoma organoids encapsulated in a gelatin methacrylate (GelMA)/polyethylene glycol diacrylate (PEGDA) hydrogel are produced. A thorough characterization of different GelMA/PEGDA ratios reveals that the mechanical properties of the bioprinted tumor model can be accurately fine-tuned to mimic a specific tumor micro-environment. Immunofluorescence and gene expression analyses of tumor markers confirm that the bioprinted synthetic hydrogel provides a flexible and adequate replacement of animal-derived reconstituted extracellular matrix.